BOSTON– Perspectum, a global medical technology company focused on quantitative imaging for metabolic, liver and multi-organ health, has entered into a strategic partnership with Avant Santé, a patient-centric contract research organization headquartered in Monterrey, Mexico, to support clinical research programs in metabolic health and liver disease across Mexico and Latin America.
The collaboration is aimed at strengthening data consistency across clinical trial sites while enabling research teams to generate high-quality evidence with patient experience and safety as central priorities.
Mexico is emerging as an increasingly important location for metabolic and liver disease research, driven by a high population disease burden and a growing emphasis on generating evidence that reflects real-world diversity. The country’s regulator, COFEPRIS, has also moved toward more streamlined and digital research protocol submissions through its DIGIPRiS platform, contributing to a more modern operating environment for sponsors and sites. These factors are positioning Mexico as a favorable setting for high-quality studies with efficient start-up and execution, particularly where standardized biomarkers can improve consistency and reduce operational variability.
Under the partnership, Perspectum’s quantitative MRI biomarkers and analytics will be integrated into Avant Santé’s research ecosystem, allowing sponsors and investigators to incorporate standardized, non-invasive imaging endpoints into studies focused on conditions such as steatotic liver disease, obesity and diabetes. By offering a coordinated joint approach, the collaboration is intended to give sponsors access to sites experienced in the combined workflow, helping shorten start-up timelines and accelerate the adoption of imaging endpoints in clinical trials.
Avant Santé provides clinical development services spanning early- and late-phase research, biomarker capabilities and real-world evidence programs, with a mission to advance drug development and drive progress in metabolic health. Perspectum’s imaging technologies are designed to complement these efforts by delivering objective, quantitative measures that align with modern research pathways and global study requirements.
As part of the agreement, the two organizations will also explore opportunities for joint scientific collaboration and education to support the development of scalable and robust research pathways for metabolic and liver disease across Latin America and beyond.
“Metabolic and liver disease are among the fastest-growing global health challenges, and sponsors need tools that are both rigorous and practical to deploy,” said Marija Mavar, president of pharma solutions at Perspectum. “For studies operating across regions such as Latin America, consistency and ease of execution at the site level are critical. Our partnership with Avant Santé supports a ready-to-deploy approach to integrating quantitative imaging into existing workflows, helping sponsors standardize measurement and generate high-quality data for global development programs.”
Dr. Sitaramaraju Yarramraju, chief executive officer and founder of Avant Santé, said the partnership reflects the organization’s commitment to building world-class clinical research capabilities in Mexico and Latin America. “Quantitative, non-invasive imaging biomarkers are increasingly critical for advancing metabolic and liver disease research, and Perspectum’s technologies complement our integrated clinical development platform,” he said. “Together, we aim to generate high-quality, globally relevant evidence while keeping patient experience, safety and scientific rigor at the centre of everything we do.”
